ワークショップ3 ドライバー遺伝子陽性肺がんに対する治療戦略

[WS3-5] Zongertinib（BI 1810631）in Patients（pts）with HER2-Driven Tumors：Beamion LUNG-1 Phase（Ph）Ia/Ib

^○Noboru Yamamoto¹, Minal Barve², Frans Opdam³, Hai-Yan Tu⁴, Yi-Long Wu⁴, David Berz⁵, Lukas Schroeter⁶, Maren Rohrbacher⁷, Behbood Sadrolhefazi⁸, John V Heymach⁹, Kiyotaka Yoh¹⁰ (1.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, 2.Mary Crowley Cancer Research, Dallas, TX, USA, 3.Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 4.Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China, 5.Valkyrie Clinical Trials, Inc., Los Angeles, CA, USA, 6.Boehringer Ingelheim Pharma GmbH ＆ Co. KG, Biberach an der Riss, Germany, 7.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 8.Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 9.Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 10.Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)